keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 147.00 | |
2 mg | In stock | $ 198.00 | |
5 mg | In stock | $ 328.00 | |
10 mg | In stock | $ 496.00 | |
25 mg | In stock | $ 945.00 | |
50 mg | In stock | $ 1,280.00 | |
100 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 428.00 |
Description | MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL). |
Targets&IC50 | BTK:1 nM(DC50) |
In vitro | MT-802 degrades BTK (DC50: 9.1 nM). The maximal degradation was observed by 250 nM. |
Molecular Weight | 787.82 |
Formula | C41H41N9O8 |
CAS No. | 2231744-29-7 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (126.93 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MT-802 2231744-29-7 Angiogenesis PROTAC Tyrosine Kinase/Adaptors BTK PROTACs inhibit MT802 Inhibitor Btk Bruton tyrosine kinase MT 802 inhibitor